Grayson Wawrzyn
Business Development Leader · Not specified
PhD in biochemistry who transitioned from R&D through program management into commercial business development roles. Now focuses on closing complex technical deals at the intersection of science, hardware, and software while building AI-native GTM systems.
Why: Nearly identical trajectory: PhD biochemistry to commercial roles with 10+ years experience. Explicitly operates at science/tech intersection and focuses on complex technical deals. Slightly less emphasis on teaching background, but strong solutions orientation and strategic account complexity.
Kim Jaffe
Chief Business Officer · BlueSphere Bio
PhD scientist who ran assays in the lab before transitioning to commercial leadership. Now converts T-cell science into strategic partnerships that advance cancer therapies from bench to market as Chief Business Officer.
Why: Quintessential bench-to-deals trajectory with PhD foundation. 'Ran the assays before she ran the deals' mirrors Sarah's molecular biology to commercial path. Strong strategic partnership focus. Less explicit AI convergence but deep biotech commercial translation.
Natalia Jiménez Lozano
R&D IT Business Partner · Nxera Pharma
PhD in Molecular Biology who became a senior business and technology leader working at the intersection of life sciences, HPC, and AI-driven drug discovery. Bridges computational modeling and biological sciences in pharmaceutical R&D.
Why: Perfect AI/biotech convergence match with PhD molecular biology background. Explicitly works at intersection of AI-driven drug discovery and life sciences. More IT/business partner role than pure account management, but strong solutions architecture orientation.
Himanshu M.
Global Client Executive · Dassault Systèmes
MSc Pharmacology with MBA who became an enterprise commercial leader in life sciences. Describes himself as fluent in three languages: science, business strategy, and technology, focusing on AI and digital twin solutions for pharma R&D.
Why: Strong parallel: scientific training (pharmacology) converted to enterprise commercial leadership. Explicitly bridges science/business/technology languages. Global client executive role mirrors strategic account focus. AI in life sciences convergence clear.
Gavin Fischer
Commercial Executive · Not specified
PhD scientist who spent 20 years specializing in the friction point between scientific discovery and commercial scaling. Architects global growth across hardware, software, and consumables with focus on bridging R&D innovation with business development.
Why: Explicitly describes career as bridging scientific discovery and commercial scaling—core Sarah trait. PhD foundation with 20 years commercial experience. Strong solutions architecture ('architecting global growth'). Less specific AI/biotech convergence but broad life sciences tech focus.
Magdalena Anna Jura
Strategic Account Management · Not specified
PhD scientist who transitioned into strategic account management and sales in pharma and biotech. Combines research management background with commercial execution, delivering results across industry segments and academia.
Why: PhD to strategic account management in pharma/biotech mirrors Sarah's path closely. Life science technologies focus with project management and sales. Less explicit AI convergence but strong academic-to-commercial translation and strategic account emphasis.
Brett Lepore
Strategic Account Manager · Sapio Sciences
Enterprise sales and business development leader commercializing AI/ML platforms and SaaS solutions across biopharma. Focuses on drug discovery platforms, LIMS, and ELN systems with quota-carrying strategic account responsibility.
Why: Perfect AI/ML in pharma convergence and strategic account management match. Drug discovery platforms align with Sarah's domain. Less clear PhD/deep scientific training, but strong commercial execution at science/tech intersection.
Anton Malyshev
Founder/CEO · ProtoBind
PhD in Neuroscience who became a biotech entrepreneur. Spent over a decade as Founder/CEO of Lactocore taking peptide drug discovery from concept to IND-ready pipeline and out-licensing. Now leads AI drug discovery company ProtoBind.
Why: PhD neuroscience to AI drug discovery entrepreneur—strong academic-to-commercial and AI/biotech convergence. More founder/entrepreneurial path than account management, but demonstrates commercial value creation from scientific foundation. Out-licensing suggests partnership/deal focus.
Benjamin Harwood
Principal Scientist | Business Development · On Target Therapeutics
PhD scientist and co-founder specializing at the intersection of AI-driven drug discovery and business development. Focuses on clinical asset strategy and pharma partnerships for CNS and pain disorders, bridging scientific expertise with commercial execution.
Why: PhD with explicit AI-driven drug discovery and business development focus. Pharma partnerships suggest strategic relationship management. Dual scientist/BD role mirrors Sarah's bridge between technical and commercial. Co-founder path differs from corporate account management trajectory.
Mohammad Alam
Automation Business Development and Technical Sales Lead · Ginkgo Bioworks
Spent 6+ years as a scientist at Ginkgo Bioworks engineering cell lines and building high-throughput screening platforms before transitioning to business development and technical sales. Now leads automation solutions engineering combining scientific and commercial expertise.
Why: Clear scientist-to-commercial transition within same company (6+ years bench science to BD/technical sales). Solutions engineering orientation strong. Autonomous labs/automation suggests tech convergence. Less explicit strategic account focus and PhD credential unclear.
